MedTrace Logo

Contrast Enhanced Mammography in the Evaluation of Cancer of Unknown Primary Syndrome

NCT06843096 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 350

Last updated 2025-02-24

No results posted yet for this study

Summary

This study aims to evaluate the role of Contrast-Enhanced Mammography (CEM) in identifying the primary tumor site in patients presenting with Cancer of Unknown Primary (CUP) syndrome. By integrating functional and anatomical imaging, the study explores CEM's diagnostic value compared to standard imaging modalities in a single-center setting.

Conditions

  • Breast Cancer Diagnosis
  • Breast Cancer Prevention

Interventions

DIAGNOSTIC_TEST

Contrast-Enhanced Mammography (CEM)

The intervention in this study involves Contrast-Enhanced Mammography (CEM), a specialized imaging technique that combines standard mammography with contrast-enhanced imaging to detect neo-angiogenesis, which is a characteristic of malignancy. Unlike traditional mammography, CEM utilizes both low-energy and high-energy images to provide enhanced visualization of tissue vascularity, aiding in the identification of occult primary tumors, particularly in patients with Cancer of Unknown Primary (CUP) syndrome. Patients who present with CUP syndrome, suspected of having a primary breast malignancy, will undergo CEM as part of their diagnostic workup. The CEM findings will be compared with other conventional imaging modalities, including ultrasound and MRI, to assess the diagnostic accuracy of CEM in detecting primary breast tumors. The intervention will also involve correlating the imaging results with histopathological findings from biopsy or surgical specimens. This study aims to demons

Sponsors & Collaborators

  • Link Campus University

    collaborator OTHER

  • University of Campania Luigi Vanvitelli

    collaborator OTHER

  • Graziella di Grezia

    lead OTHER

Principal Investigators

  • Graziella Di Grezia, medicine and surgery · Link Campus University

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-01
Primary Completion
2025-03-01
Completion
2026-01-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06843096 on ClinicalTrials.gov